Johnson & Johnson is earmarking nearly USD 9 billion to cover allegations that its baby power containing talc caused cancer, more than quadrupling the amount that the company had previously set aside to pay for its potential liability.
Under a proposal announced Tuesday, a J&J subsidiary will re-file for Chapter 11 bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history.
The USD 8.9 billion that J&J would transfer to the subsidiary, LTL Management, would be payable over the next 25 years. The amount is up from the USD 2 billion that the New Brunswick, New Jersey, company set aside in October 2021.
Read also: J&J’s different strokes on its baby talc continue to raise questions
The revised amount is being backed by more than 60,000 parties that have filed lawsuits alleging harm from J&J talcum powder, according to the company.
J&J isn't admitting any wrongdoing as part of the proposed settlement, a point that company executive emphasised in a Tuesday statement that maintained the claims “are specious and lack scientific merit.” But fighting the lawsuits in court would take decades and be expensive, said Erik Haas, J&J's worldwide vice president of litigation.
The lawsuits filed against J&J had alleged its talcum powder caused users to develop ovarian cancer, through use for feminine hygiene, or mesothelioma, a cancer that strikes the lungs and other organs.
The claims contributed to drop in J&J's sales of baby powder, prompting the company to stop selling its talc-based products in 2020. Last year, J&J announced plans to cease sales of the product worldwide.
J&J's stock rose 3 per cent in after-hours trading Tuesday after the company's announcement.